Clinical Trial Update: SB17170 Phase 2 Trial in IPF Patients [Phase 2]

View source ↗

Summary

SPARK Biopharma is conducting a Phase 2 trial of SB17170 in patients with idiopathic pulmonary fibrosis and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• SB17170

Snippet

Sponsor: SPARK Biopharma | Conditions: IPF, Idiopathic Pulmonary Fibrosis | Phase 2 | Status: RECRUITING